Clinical Trials · NCT00092287

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

Name: Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

TerminatedPhase 3Octreotide Lanreotide

Phase: Phase 3
Recruitment status: Terminated
Sponsor: Ipsen
Enrollment: 4
Start date: Jul 2004
Locations: 1 site, United States
Primary endpoint: Target symptom frequency (flushing or stool frequency).

View Octreotide compound reference